PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17351648-3 2007 Cyclosporine and rapamycin reduce the expansion of effector T cells by blocking interleukin (IL)-2, but signaling by IL-2 is pivotal for T(REG) homeostasis. Sirolimus 17-26 interleukin 2 Mus musculus 80-98 18768852-7 2008 Skin gammadelta T cells treated with rapamycin are refractory to IL-2 stimulation and attempt to survive in the absence of cytokine and growth factor signaling by undergoing autophagy. Sirolimus 37-46 interleukin 2 Mus musculus 65-69 19332874-6 2009 Pretreating with the IL-2-IL-2 mAb complexes renders the mice resistant to induction of experimental autoimmune encephalomyelitis; combined with rapamycin, the complexes can also be used to treat ongoing disease. Sirolimus 145-154 interleukin 2 Mus musculus 21-25 19332874-6 2009 Pretreating with the IL-2-IL-2 mAb complexes renders the mice resistant to induction of experimental autoimmune encephalomyelitis; combined with rapamycin, the complexes can also be used to treat ongoing disease. Sirolimus 145-154 interleukin 2 Mus musculus 26-30 11872661-4 2002 Similarly, sirolimus and IL-2 were synergistic in protecting syngeneic islet grafts from recurrent autoimmune destruction after transplantation in diabetic NOD mice, and diabetes did not recur after stopping sirolimus and IL-2 combination therapy. Sirolimus 11-20 interleukin 2 Mus musculus 222-226 11872661-3 2002 We found that sirolimus and IL-2 therapy of female NOD mice, beginning at age 10 weeks, was synergistic in preventing diabetes development, and disease prevention continued for 13 weeks after stopping sirolimus and IL-2 therapy. Sirolimus 14-23 interleukin 2 Mus musculus 215-219 11872661-3 2002 We found that sirolimus and IL-2 therapy of female NOD mice, beginning at age 10 weeks, was synergistic in preventing diabetes development, and disease prevention continued for 13 weeks after stopping sirolimus and IL-2 therapy. Sirolimus 201-210 interleukin 2 Mus musculus 28-32 15010863-4 2004 The phosphorylation and activity of PKB/Akt in IL2-stimulated CTLL2 cells were rapamycin-insensitive and reduced upon wortmannin treatment of the cells, confirming a requirement for PI-3K for Akt activity. Sirolimus 79-88 interleukin 2 Mus musculus 47-50 11872661-4 2002 Similarly, sirolimus and IL-2 were synergistic in protecting syngeneic islet grafts from recurrent autoimmune destruction after transplantation in diabetic NOD mice, and diabetes did not recur after stopping sirolimus and IL-2 combination therapy. Sirolimus 208-217 interleukin 2 Mus musculus 25-29 11935154-9 2002 Islet grafts from sirolimus plus tacrolimus-treated mice expressed significantly decreased mRNA contents of Th1-type cytokines (IFN- gamma and IL-2) and the highest ratio of TGF- beta1/IFN- gamma mRNA. Sirolimus 18-27 interleukin 2 Mus musculus 143-147 11935154-10 2002 CONCLUSION/INTERPRETATION: These findings suggest that combination therapy with sirolimus and tacrolimus prevent autoimmune beta-cell destruction by upregulating expression of the immunoregulatory cytokine, TGF- beta1 and reducing Th1 cytokines (IFN- gamma and IL-2) expressed in the islets. Sirolimus 80-89 interleukin 2 Mus musculus 261-265 11355896-0 2001 Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. Sirolimus 0-9 interleukin 2 Mus musculus 17-21 11355896-6 2001 Rapamycin also preserves cell survival by keeping intact the IL-2-induced cell survival programs. Sirolimus 0-9 interleukin 2 Mus musculus 61-65 10605009-9 2000 Glycine and rapamycin caused dose-dependent decreases in IL-2-stimulated growth of Ctll-2 cells to about 60% and 40%, respectively, of control. Sirolimus 12-21 interleukin 2 Mus musculus 57-61 10376934-2 1999 Proliferation and selected IL2-driven gene expression are blocked by treatment with rapamycin. Sirolimus 84-93 interleukin 2 Mus musculus 27-30 9566798-7 1998 In contrast, immune lymph node cells from mice that had been treated in vivo with rapamycin gave optimal antigen-specific proliferation and IL-2 production in vitro. Sirolimus 82-91 interleukin 2 Mus musculus 140-144 7728769-3 1995 To determine whether this pathway plays a role in the regulation of apoptosis, we assessed the effect of rapamycin on apoptosis induced by interleukin 2 deprivation in murine T-cell lines, by T-cell receptor ligation in a murine T-cell hybridoma, by enforced c-myc expression in murine fibroblasts, and by corticosteroids in murine T-lymphoma cell lines. Sirolimus 105-114 interleukin 2 Mus musculus 139-152 8943845-5 1996 The IL-2-mediated induction of BAG-1 expression required the activation of tyrosine kinase(s) and was sensitive to rapamycin as the induction of bcl-2 expression was. Sirolimus 115-124 interleukin 2 Mus musculus 4-8 1987692-4 1991 Similarly, cyclosporine potentiated the inhibitory effects of rapamycin upon proliferation of IL-2 (CTLL-2) and IL-6 (MH60.BSF-2) lymphokine-dependent cell lines. Sirolimus 62-71 interleukin 2 Mus musculus 94-98 7520778-1 1994 The immunosuppressive drug rapamycin suppresses T-cell activation by impairing the T-cell response to lymphokines such as interleukin-2 (IL-2) and interleukin-4 (IL-4). Sirolimus 27-36 interleukin 2 Mus musculus 122-135 7520778-1 1994 The immunosuppressive drug rapamycin suppresses T-cell activation by impairing the T-cell response to lymphokines such as interleukin-2 (IL-2) and interleukin-4 (IL-4). Sirolimus 27-36 interleukin 2 Mus musculus 137-141 8376945-6 1993 Also, cells exposed to IL-2 in the presence of rapamycin showed full Erk2 activation but not DNA synthesis. Sirolimus 47-56 interleukin 2 Mus musculus 23-27 7721872-0 1995 Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte. Sirolimus 0-9 interleukin 2 Mus musculus 29-42 7721872-8 1995 Rapamycin inhibited the IL-2-induced PCNA mRNA, and the murine PCNA promoter activity in IL-2-stimulated cells. Sirolimus 0-9 interleukin 2 Mus musculus 24-28 7721872-8 1995 Rapamycin inhibited the IL-2-induced PCNA mRNA, and the murine PCNA promoter activity in IL-2-stimulated cells. Sirolimus 0-9 interleukin 2 Mus musculus 89-93 7518620-4 1994 Using this method, we studied the time course and effects of CsA and rapamycin on IL-2, IFN-gamma, IL-4, and IL-10 gene expression following Con A stimulation. Sirolimus 69-78 interleukin 2 Mus musculus 82-86 8109837-2 1993 In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle. Sirolimus 72-81 interleukin 2 Mus musculus 6-19 8109837-2 1993 In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle. Sirolimus 72-81 interleukin 2 Mus musculus 21-25 8109837-2 1993 In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle. Sirolimus 158-167 interleukin 2 Mus musculus 6-19 8109837-2 1993 In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle. Sirolimus 158-167 interleukin 2 Mus musculus 21-25 8109837-2 1993 In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle. Sirolimus 158-167 interleukin 2 Mus musculus 182-186 8109837-4 1993 These results demonstrate a rapamycin-sensitive IL-2-dependent signaling pathway in T cells and suggest that the immunosuppressive properties of rapamycin are mediated by impinging on the IL-2-induced T cell expression of p34cdc2. Sirolimus 28-37 interleukin 2 Mus musculus 48-52 8109837-4 1993 These results demonstrate a rapamycin-sensitive IL-2-dependent signaling pathway in T cells and suggest that the immunosuppressive properties of rapamycin are mediated by impinging on the IL-2-induced T cell expression of p34cdc2. Sirolimus 28-37 interleukin 2 Mus musculus 188-192 7690317-3 1993 In mouse systems, rapamycin caused a dose-dependent inhibition of both Ca(2+)-dependent (concanavalin A (Con A), phytohemagglutinin (PHA), and phorbol 12-myristate 13-acetate + ionomycin) and Ca(2+)-independent (lipopolysaccharide and PMA + interleukin-2) activation, whereas in the rat only Ca(2+)-independent responses were inhibited. Sirolimus 18-27 interleukin 2 Mus musculus 241-254 1380162-7 1992 Rapamycin, a macrolide immunosuppressant that inhibits IL-2-dependent proliferation, inhibited IL-2-stimulated 70-kDa S6 kinase activity subsequent to early increases in tyrosine kinase activity. Sirolimus 0-9 interleukin 2 Mus musculus 55-59 1380162-7 1992 Rapamycin, a macrolide immunosuppressant that inhibits IL-2-dependent proliferation, inhibited IL-2-stimulated 70-kDa S6 kinase activity subsequent to early increases in tyrosine kinase activity. Sirolimus 0-9 interleukin 2 Mus musculus 95-99 1723403-6 1991 Cyclosporin A and ascomycin did not inhibit interleukin 2 dependent proliferation, whereas the dunaimycins and rapamycin blocked the uptake of [3H]thymidine in mixed cultures supplemented with exogenous interleukin 2. Sirolimus 111-120 interleukin 2 Mus musculus 203-216 34912349-4 2021 As previously shown by our group, injecting mice with IL-2/anti-IL-2 complexes (IL-2cplx) to augment expansion of CD4 T regulatory cells (Tregs) induces tolerance towards islet allografts, and also to skin allografts when IL-2cplx treatment is supplemented with rapamycin and a short-term treatment of anti-IL-6. Sirolimus 262-271 interleukin 2 Mus musculus 54-58 18089405-0 2007 Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation. Sirolimus 90-99 interleukin 2 Mus musculus 20-23 18089405-0 2007 Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation. Sirolimus 90-99 interleukin 2 Mus musculus 33-36 32459545-3 2021 Although injection of IL-2 complex alone was not capable of decreasing the clinical score of EAU, injection of IL-2 complex/rapamycin significantly delayed the onset of EAU. Sirolimus 124-133 interleukin 2 Mus musculus 111-115 20086156-3 2010 Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation. Sirolimus 54-63 interleukin 2 Mus musculus 175-179 24658577-8 2014 Furthermore, Rapamycin promoted Treg expansion and inducible Treg generation in allogeneic BMT recipients treated with IL-2. Sirolimus 13-22 interleukin 2 Mus musculus 119-123 24658577-9 2014 Consistent with these observations, CsA abrogated while Rapamycin promoted the protective effect of IL-2 on allogeneic BMT-induced GVHD. Sirolimus 56-65 interleukin 2 Mus musculus 100-104 23670972-6 2013 Also, we observed that RAPA counteracted IL-2 effects on Treg cells, failed to control IL-2-boosted NK cells, and broke IL-2-induced tolerance in a reversible way. Sirolimus 23-27 interleukin 2 Mus musculus 41-45 25394722-0 2014 Administration of low doses of IL-2 combined to rapamycin promotes allogeneic skin graft survival in mice. Sirolimus 48-57 interleukin 2 Mus musculus 31-35 23105977-7 2012 Intranasal rapamycin attenuated lung MCP-1, IL-2, IL-6, and IFNgamma by 70%, 30%, 64%, and 68% respectively. Sirolimus 11-20 interleukin 2 Mus musculus 44-48